Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians evaluate and discuss early signs of progression to secondary progressive MS
- Up to 80% of relapsing remitting MS (RRMS) patients transition to secondary progressive MS (SPMS)[1], a stage of the disease leading to continuous functional decline, which is often undiagnosed or diagnosed only retrospectively[2]?
- Data presented at AAN show that MSProDiscussTM, a scientifically-validated digital tool, was able to provide information to support differentiation between RRMS and SPMS with high sensitivity and specificity?
- These findings support potential use of the tool in clinical practice to help evaluate and discuss early signs suggestive of MS progression, an important step to ensure optimal management of the disease
# # #
Novartis Media Relations Central media line: +41 61 324 2200 E-mail:?media.relations@novartis.com